Adenoid cystic carcinoma is a malignant tumour commonly originating from the salivary glands, but can rarely arise from the upper airway and be life threatening when the central airway is compromised. While surgical resection is considered the definitive treatment, adenoid cystic carcinoma of the airway is frequently unresectable for a variety of reasons including tumour size, location, local extension, or patient comorbidities. There is no consensus on the best treatment for locally advanced inoperable adenoid cystic carcinoma of trachea. This case report describes a 32-year-old woman with inoperable adenoid cystic carcinoma of trachea successfully managed in our institution using a multimodality approach: endoscopic stenting followed by 3-dimensional conformal radical radiotherapy. Previous literature on the management of this rare disease is also reviewed.
INTRODUCTION
Adenoid cystic carcinoma (ACC) is a malignant tumour commonly found in the salivary glands. Cases of ACC of the trachea are very rare. The incidence of tracheal tumour only accounts for 0.09% to 0.2% of all cancers and most of them are squamous cell carcinomas; only 10% of the cases are ACCs. 1, 2 Most patients with ACC of trachea present with dyspnoea and wheezing. Long latency is usually observed between symptom presentation and diagnosis due to its slow pace of growth. Despite its slow progression, it can be locally infiltrative and lifethreatening when causing central airway obstruction which may necessitate emergency management. Surgical excision is usually the mainstay of treatment. Unfortunately, it is frequently unresectable for a variety of reasons like tumour size, location, local extension, or patient comorbidities. The standard treatment for locally advanced inoperable ACC of trachea is yet to be defined.
Here we present a case of inoperable ACC of trachea managed with multimodality treatment in our institution.
CASE REPORT
A 32-year-old Chinese female presented with chronic cough for 1 year in March 2011. She had worsening of symptoms with copious sputum and increasing shortness of breath. Her exercise tolerance gradually decreased to being able to climb just three flights of stairs. Chest X-ray showed collapse of the left lung with tracheal deviation (Figure 1 ). Computed tomography (CT) scan of the thorax and abdomen showed a soft tissue mass in the left subcarinal region compressing the lumen of left main bronchus and abutting the right main pulmonary artery and superior vena cava. There was no regional lymph node involvement or distant metastasis.
Flexible bronchoscopy found a tumour extending from the carina down to the left main bronchus with complete obstruction. Biopsy confirmed ACC (Figure 2 ). While undergoing these investigations, she had deterioration with increasing dyspnoea and required oxygen therapy. Arterial blood gas, while on 50% oxygen mask, revealed type I respiratory failure (pO 2 = 4.24 kPa; reference range, 10.7-13.3 kPa). Transluminal placement of tracheobronchial stent was urgently performed and symptoms were immediately relieved; oxygen was weaned off later. Results of arterial blood gas checked post-stenting were normalised.
Surgical resection was contraindicated in view of its extensive local invasion from the carina down to the left main bronchus, and close proximity to the major vessels. Even pneumonectomy with excision of the tumour would be of R2 resection with macroscopic residual disease and would put the patient at high risk of postoperative complications. Our patient then received 3-dimensional (3D) conformal radical radiotherapy with 60 Gy in 30 fractions over 6 weeks. The treatment was well-tolerated with only grade 1 odynophagia; she completed the whole treatment.
Post-treatment serial CT scans did not show any disease progression or metastasis. The 24-month post-treatment CT scan also revealed complete remission with reexpansion of the left lung (Figures 3 and 4) . The patient resumed work and was enjoying a normal life.
DISCUSSION
The incidence of tracheal tumours is less than 0.2 per 100,000 people per year. There is no sex predilection and smoking is not associated with this disease. 1, 2 Complete surgical resection is usually the definitive treatment for tracheal ACC. The median survival time of patients after operation has been reported to range from 7.5 to 118 months. The complete resection rates reported range from 42% to 57%. Gaissert et al 3 published the largest series of tracheal ACC, including 135 patients in 40 years. Of these, 71% were treated with resection and the 5-year overall survival was 52%. They demonstrated that long-term survival was significantly associated with complete resection and negative airway margins. Unfortunately, ACC tends to infiltrate along the airways, making it difficult for complete resection. Alternative treatments are needed but sparingly reported in the literature. Definitive radiotherapy has produced mixed results, with a local control rate ranging from 20% to 70%. Maziak et al 4 reported good results in six patients who received primary radiotherapy for inoperable ACCs, with a mean survival of 74 months (range, 1-172 months). The majority of cases treated with definitive radiotherapy died later from local recurrence. 4 Contouring and planning for radiotherapy, nonetheless, take some time to complete. Some patients may develop life-threatening airway obstruction while awaiting radiotherapy. In addition, radiotherapy may not provide immediate symptom relief for patients with ACC as the tumour is not very radiosensitive. Early intervention with bronchoscopic guidance can solve this problem and allow more time for complete investigation and comprehensive and sophisticated radiotherapy planning. There are various kinds of bronchoscopic interventions including mechanical dilatation with rigid tube, ballooning, minimally invasive debulking surgery, stent insertion, and laser resection. 5 Tracheobronchial stent insertion was found to be helpful for our patient in relieving dyspnoeic symptoms before starting radiotherapy.
Despite the fact that there are few publications on radiotherapy in ACC, different approaches are being explored in an attempt to improve treatment outcomes. These new approaches are focused on the dose of radiotherapy, new radiation techniques, and use of concurrent chemoradiotherapy.
Dose of Radiotherapy
There may be a dose-response relationship between dose of radiotherapy and treatment outcomes of ACC. Some retrospective series demonstrated a more favourable treatment outcome when more than 60 Gy was given.
6,7 Kanematsu et al 6 reported the outcomes of five patients who received definitive radiotherapy at a median dose of 60 Gy (range, 50-70 Gy). One patient had complete response while the others had partial response. 6 Recently, Bonner Millar et al 7 also reported the outcomes of two patients with tracheal ACC treated with definitive radiotherapy with a dose up to 80 Gy. The two patients continued to show complete response during their 11-month and 5-year follow-up scans, respectively, 7 suggesting that such a high dose was feasible and safe when highly conformal treatment techniques are implemented.
Our patient showed complete remission on her 24-month post-treatment scan. This demonstrates that a dose of 60 Gy could provide long-term control in inoperable ACCs.
New Radiotherapy Technique
Studies have shown that intensity-modulated radiation therapy (IMRT) and / or image-guided radiation therapy (IGRT) improves the overall survival and local control while simultaneously decreases the risk of radiation pneumonitis in stage III non-small-cell lung cancer when treated with concurrent chemotherapy.
8 Compared with 3D conformal technique, IMRT plans provide superior tumour coverage and better sparing of critical normal structures. Use of IMRT and / or IGRT with dose escalation may be the new approach for treating ACC in the near future.
In addition, particle radiotherapy has become more popular and been under research for treatment of various malignancies. Bittner et al 9 described 20 cases with unresectable ACCs treated with upfront neutron therapy. The 5-year actuarial survival rate was 89.4%, median survival was 97 months, and 5-year local control rate was 54.1%. 9 However, only a few established institutions have such facility which is also costly. Larger studies are needed to elucidate the role of this modality for treating this rare disease.
Stereotactic hypofractionated radiotherapy for inoperable, early-stage non-small-cell lung cancer has been well-established. It has a high local control rate of more than 90% at 3 years. 10 However, most of the ACCs of airways lie in the 'no fly zone' defined as within 2 cm of the tracheobronchial tree. Thus, the practicability and safety of stereotactic hypofractionated radiotherapy for tracheal ACC remain unanswered questions.
Concurrent Chemoradiotherapy
Concurrent platinum-based chemoradiotherapy has been the standard treatment of locally advanced nonsmall-cell lung cancer. The 2004 Cochrane review reported a significant reduction in risk of death at 2 years (relative risk, 0.93; 95% confidence interval [CI], 0.88-0.98; p = 0.01) for concurrent chemoradiotherapy compared with radiotherapy alone.
11 Moreover, a metaanalysis using individual patient data in 2007 reported a significant overall survival benefit of concurrent chemoradiotherapy compared with sequential chemoradiotherapy (hazard ratio, 0.83; 95% CI, 0.73-0.94; p = 0.0026). There was an absolute survival benefit of 6.6% at 3 years (from 18.2% with sequential treatment to 24.8% with concomitant treatment).
12
Although there is not much evidence on radical chemoradiotherapy for ACC of the airway, Allen et at 13 reported the case of a patient who underwent chemoradiotherapy using weekly carboplatin and paclitaxel. That patient showed complete response in his 3-month post-treatment CT scan with tolerable side-effects. Longer surveillance and further research are needed to compare chemoradiotherapy with radiotherapy alone, and to derive the most suitable chemotherapy regimen.
CONCLUSION
Although ACC of the airway can be locally invasive and inoperable, this does not preclude a patient from receiving radical treatment. Further studies are warranted to investigate room for improvement in treatment outcome.
